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Objectives
Discussion
Background
Direct oral anticoagulants (DOACs) include anti-IIa agent
(dabigatran etexilate) and anti-Xa agents (rivaroxaban,
apixaban and edoxaban). DOACs do not require monitoring nor
frequent dose adjustment. However, searching for the optimal
response at the individual patient level may be useful in some
situations. Activated partial thromboplastin time, Hemoclot
Thrombin Inhibitor® (HTI) and ecarin clotting time have been
proposed to monitor dabigatran whereas anti-Xa chromogenic
assays are preferable to monitor anti-Xa agents1,2,3. However,
there is still a need for a global test easily implementable and
widely available that may be used for all DOACs. Recent
studies showed that the dilute Russell Viper Venom Time
(DRVV-T) could be used for the monitoring of DOACs but these
results have not been performed on clinical samples4.
To analyse and compare the results obtained with
STA®-DRVV Screen and STA®-DRVV Confirm with the
plasma drug levels measured by LC-MS/MS.
60 plasmas from patients treated with rivaroxaban and 48 
plasmas from patients treated with dabigatran etexilate
were included in the study. Plasma concentrations were 
measured by LC-MS/MS. STA®-DRVV Screen and Confirm 
(Diagnostica Stago®) were performed on the 108 plasma 
samples. All methodologies were performed according to 
the recommendations of the manufacturer.
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- The DRVV cannot be used to accurately
estimate dabigatran and rivaroxaban
plasma concentrations
- Specific cut-off could however be proposed
to rule out excessive concentrations (i.e.
concentrations > 200ng/mL at Ctrough)
- However, these cut-offs are specific for
dabigatran and rivaroxaban due to
difference in sensitivities and also depend
on the quantity of phospholipid in the test.
STA®-DRVV Screen
Figure 1: Correlation between STA®-DRVV
Screen and dabigatran or rivaroxaban plasma
concentraitons. Results are expressed in seconds
(A), as ratio (B) or in ng/mL (C). Graphic of the
Bland-Altman analysis (D) comparing the two
methods for results expressed in ng/mL is also
provided. For the Bland Altman analysis the
difference is calculated as follow: [difference (A-B)
vs. average] where A is the result of the LC-MS/MS
and B the result of calibrated STA®-DRVV Screen
.
STA®-DRVV Confirm
Figure 2: Correlation between STA®-DRVV
Confirm and dabigatran or rivaroxaban plasma
concentration. Results are expressed in seconds
(A), as ratio (B) or in ng/mL (C). Graphic of the
Bland-Altman analysis (D) comparing the two
methods for results expressed in ng/mL is also
provided. For the Bland Altman analysis the
difference is calculated as follow: [difference (A-B)
vs. average] where A is the result of the LC-MS/MS
and B the result of calibrated STA®-DRVV Confirm
.
Results
Discussion
The dabigatran plasma concentration ranged from 0 to 413ng/mL and the rivaroxaban plasma concentration ranged from 0 to 426ng/mL.
Correlation between STA®-DRVV Screen and LC-MS/MS measurements
Calibrated STA®-DRVV Screen and dabigatran or rivaroxaban plasma concentrations correlate well (Figures 1 C). The Spearman correlation is 0.84 (95% CI: 0.72 – 0.91; p<0.0001) and
0.88 (95% CI: 0.82 – 0.93) for dabigatran and rivaroxaban, respectively. When expressed in seconds or as ratios the relation is not linear and is best fit by a second order relation (Figures
1 A & B). Results of the Bland-Altman analysis reveal a mean difference of -37ng/mL and -21ng/mL for dabigatran and rivaroxaban, respectively, with large confidence interval.
This implies that STA®-DRVV Screen tends to overestimate the concentration of dabigatran and rivaroxaban in plasma samples. Therefore STA®-DRVV Screen should not be used to
estimate plasma concentrations of both dabigatran and rivaroxaban. However, specific cut-off associated with supra-therapeutic concentrations at Ctrough (i.e. 200ng/mL which represent
the 90th percentile of plasma concentrations at Ctrough) could be defined. Thus, a ratio of 2.5 or 3.0 could exclude plasma concentration above 200ng/mL for dabigatran and rivaroxaban,
respectively.
Correlation between STA®-DRVV Confirm and LC-MS/MS measurements
Calibrated STA®-DRVV Confirm and dabigatran or rivaroxaban plasma concentrations correlate well (Figures 2 C). The Spearman correlation is 0.94 (95% CI: 0.89 – 0.97; p<0.0001) and
0.89 (95% CI: 0.82 – 0.94; p<0.0001) for dabigatran and rivaroxaban, respectively. When expressed in seconds or as ratios the relation is not linear and is best fit by a second order
relation (Figures 2 A & B). Results of the Bland-Altman analysis reveal a mean difference of -40ng/mL and -16ng/mL with large confidence interval for dabigatran and rivaroxaban,
respectively.
This implies that STA®-DRVV Confirm tends to overestimate the concentration of dabigatran and rivaroxaban in plasma samples. Therefore STA®-DRVV Confirm should not be used to
estimate plasma concentrations of both dabigatran and rivaroxaban. As for STA®-DRVV Screen, specific cut-off could be proposed and a ratio of 1.8 or 2.5 at Ctrough with STA®-DRVV
Confirm could exclude supra-therapeutic levels of dabigatran and rivaroxaban, respectively.
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